Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab compared to PD-L1 at the upcoming National ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback